SPARTEINE SULFATE ANHYDROUS

US Previously Marketed

First marketed in 1921

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H26N2.H2O4S
Molecular Weight	332.459
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of SPARTEINE SULFATE ANHYDROUS

Structure Search

SMILES

OS(O)(=O)=O.[H][C@]12CN3CCCC[C@@]3([H])[C@]([H])(CN4CCCC[C@]14[H])C2

InChI

InChIKey=FCEHFCFHANDXMB-UMEYXWOPSA-N

InChI=1S/C15H26N2.H2O4S/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17;1-5(2,3)4/h12-15H,1-11H2;(H2,1,2,3,4)/t12-,13-,14-,15+;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C15H26N2
Molecular Weight	234.3803
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H2O4S
Molecular Weight	98.078
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB06727
Curator's Comment: Description was created based on several sources, including http://www.ndrugs.com/?s=spal

Sparteine is a class 1a antiarrhythmic agent; a sodium channel blocker. It is the predominant alkaloid in Lupinus mutabilis, and is thought to chelate the bivalents calcium and magnesium. It is not FDA approved for human use as an antiarrhythmic agent. It is also used as a chiral base in organic chemistry, and as a ligand in organic chemical synthesis. Marketed under the brand name Spal in Taiwan and Sparteine in Brazil.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
sodium ion transport 14 Target ID: GO:0006814 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9781689	Inhibitor 8297		168.8 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Arrhythmia 38 Sources: http://www.ndrugs.com/?s=spal	Primary		Approved 8429	Spal Approved Use Indications: arrhythmias

T_1/2

Value	Dose	Co-administered	Analyte	Population
117.8 min EXPERIMENT https://link.springer.com/article/10.1007/BF00404298	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:		SPARTEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
117.45 min EXPERIMENT https://link.springer.com/article/10.1007/BF00404298	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		SPARTEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
50% EXPERIMENT https://link.springer.com/article/10.1007/BF00404298	single, unknown		SPARTEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
		substrate 1217	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	OCT1 327 OCT2 355 OCT3 80 MATE1 135

Drug as victim

Target	Modality	Activity
CYP2D6 1217	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/9731719/ \| https://pubmed.ncbi.nlm.nih.gov/21297307/ \| https://pubmed.ncbi.nlm.nih.gov/8513845/	yes
MATE1 135	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/33434947/	yes
OCT1 327	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/33434947/	yes
OCT2 355	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/33434947/	yes
OCT3 80	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/33434947/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://edoc.unibas.ch/34476/1/PhD%20thesis_Anja%20Schramm.pdf Page: 45.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:28827	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28827
ChemicalBook	CB4674283	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4674283
MolPort	MolPort-003-987-414	https://www.molport.com/shop/molecule-link/MolPort-003-987-414
ZINC	ZINC000001408502	http://zinc15.docking.org/substances/ZINC000001408502
eMolecules	1936017	https://www.emolecules.com/cgi-bin/more?vid=1936017

PubMed

Title	Date	PubMed
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.	2001 Aug	11505218
Scope of enantioselective palladium(II)-catalyzed aerobic alcohol oxidations with (-)-sparteine.	2003 May 30	12762783

Patents

Sample Use Guides

In Vivo Use Guide

A single 100 mg oral dose of sparteine and a single 40 mg oral dose of dextromethorphan were administered on two occasions to 12 patients

Route of Administration: Oral

In Vitro Use Guide

Sparteine (20 uM) produced also remarkable inhibitions in the uptake of [3H]-histamine by astrocytes from rat brain.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:04:16 GMT 2023` Edited by `admin` on `Fri Dec 15 15:04:16 GMT 2023`
Record UNII	3D76XVF9R0
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SPARTEINE SULFATE ANHYDROUS

Common Name

English

NSC-143087

Code

English

Sparteine sulfate anhydrous [WHO-DD]

Common Name

English

SPARTEINE SULPHATE ANHYDROUS

Common Name

English

Code System Code Type Description

FDA UNII

3D76XVF9R0